AMERICAN NATUROPATHIC RESEARCH INSTITUTE
NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE
1250 E. Baseline Rd., Suite 205
Tempe, AZ 85283
JOINT MEETING OF THE
AMERICAN NATUROPATHIC RESEARCH INSTITUTE (ANRI)
NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE (NORI)
INTERNATIONAL NATUROPATHIC CLINICAL RESEARCH INSTITUTE
INSTITUTIONAL REVIEW BOARD (IRB)
August 11, 2017
MINUTES AND MEETING NOTES
In accordance with the requirements of the United States Code of Federal Regulations, Title 21, Chapter 1, Subchapter A, Part 56, the thirty-first regular quarterly meeting of the American Naturopathic Research Institute (ANRI) and the Naturopathic Oncology Research Institute (NORI) and the International Naturopathic Clinical Research Institute (INCRI) and the Institutional Review Board (IRB) was called to order at 12:00 p.m., August 11, 2017 at 1250 E. Baseline Rd., Suite 205, meeting in Suite 203, Tempe, AZ 85283.
MEMBERS AND GUESTS
15 members and guests were in attendance. This included 12 physicians and 3 non-physicians.
AZND BOARD RESPONSE TO GOV. DUCEY EXECUTIVE ORDER
As requested by AZ Governor Doug Ducey, Gail Anthony of our Board responded with explanation of the value of the Board in AZ and reasons for retaining separation of our Board from other health professional boards.
QUICK RECAP OF A RECENT COURT CASE INVOLVING MEDICAL EXEMPTION TO VACCINES WRITTEN BY A NMD
The Judge in a recent divorce and custody case upheld the medical exemption written by a naturopathic physician, and the judge wrote: “It is ordered denying Respondent’s Petition to Mandate Immunization Shots to Minor Child.” Details and references were shared.
BASTYR UNIVERSITY’S RECENT SUCCESS AGAINST DEFAMATION
A career anti-naturopath living in Germany defamed Bastyr University on a blog and webpages, among other venues. Bastyr sent her a Cease and Desist letter, through a European attorney. The defamer then posted that entire letter on her website. Within a few days, the defamatory pages against Bastyr had broken links. The group generally found this to be a pleasing outcome.
UPDATE OF RECENT DEVELOPMENTS AT FDA
Recent developments at the FDA were discussed.
Laetrile was brought up as an historically controversial cancer treatment, the use of which in the US seems to date back to 1844. A well-known conflict over its outcomes and use took place at Memorial Sloan Kettering Institute in New York in the 1970s, and its legal status has been reversed a number of times. It is therefore not widely used in the US at this time. The group discussed and voted on whether this substance should be reviewed by this IRB.
OTHER RESEARCH POSSIBILITIES
We discussed other research that may be available for this IRB to review in the near future.
Access to Mistletoe as well as two patient cases were discussed.
LYME DISEASE STUDY
A student at SCNM came from one of the physician’s offices. They have been studying a substance that they are using with Lyme’s patients. Questions were asked and suggestions were made.
The group voted unanimously to have the research proceed as discussed.
The next meeting will be held on Friday, November 17, 2017 at noon, the usual place.